logo-loader
viewPropanc Biopharma Inc

Propanc Biopharma boosts its patent portfolio for its anti-cancer therapy

Propanc Biopharma Inc (OTCMTKS:PPCBD) CEO James Nathanielsz tells Proactive Investors the company has boosted its intellectual property portfolio for its anti-cancer technology currently in development.

The biopharmaceutical company’s portfolio now has 65 patents either in force or pending in most major countries around the globe. Nathanielsz also updated investors on the reasoning behind the company's recent reverse stock split.

Quick facts: Propanc Biopharma Inc

Price: 0.83 USD

OTCMKTS:PPCB
Market: OTCMKTS
Market Cap: $971.12 k
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Propanc Biopharma Inc named herein, including the promotion by the Company of Propanc Biopharma Inc in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Propanc Biopharma appoints Ralf Brandt to scientific advisory board as it...

Propanc Biopharma Inc (OTCMKTS:PPCB) chief executive officer James Nathanielsz speaks to Procative Investors about the company's recent appointment of Dr Ralf Brandt to its scientific advisory board.   The company is developing patents for cancer treatment that focuses on solid...

on 05/15/2019

2 min read